This would favor the HIV-DNA prime HIV-MVA boost vaccine strategy over HIV-DNA priming and CN54 rgp140/GLA-AF coadministration with HIV-MVA, since Gottardo et al. [39] found the presence of anti-V3 plasma IgG to be correlated with reduced infection risk only in RV144 participants with low anti-Env plasma IgA. This evidence concerns the gene CD79A and infection.